ATE205479T1 - Naphtalen-derivate als prostaglandin i2 agonisten - Google Patents
Naphtalen-derivate als prostaglandin i2 agonistenInfo
- Publication number
- ATE205479T1 ATE205479T1 AT95910763T AT95910763T ATE205479T1 AT E205479 T1 ATE205479 T1 AT E205479T1 AT 95910763 T AT95910763 T AT 95910763T AT 95910763 T AT95910763 T AT 95910763T AT E205479 T1 ATE205479 T1 AT E205479T1
- Authority
- AT
- Austria
- Prior art keywords
- naphtalen
- prostaglandin
- agonists
- derivatives
- hydroxy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/12—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/26—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring
- C07C271/28—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring to a carbon atom of a non-condensed six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C281/00—Derivatives of carbonic acid containing functional groups covered by groups C07C269/00 - C07C279/00 in which at least one nitrogen atom of these functional groups is further bound to another nitrogen atom not being part of a nitro or nitroso group
- C07C281/02—Compounds containing any of the groups, e.g. carbazates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/14—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
- C07D303/02—Compounds containing oxirane rings
- C07D303/12—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
- C07D303/16—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by esterified hydroxyl radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Epoxy Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9404734A GB9404734D0 (en) | 1994-03-10 | 1994-03-10 | Heterocyclic compounds |
| GB9407036A GB9407036D0 (en) | 1994-04-08 | 1994-04-08 | Naphthalene derivatives |
| PCT/JP1995/000373 WO1995024393A1 (en) | 1994-03-10 | 1995-03-08 | Naphthalene derivatives as prostaglandin i2 agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE205479T1 true ATE205479T1 (de) | 2001-09-15 |
Family
ID=26304472
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT95910763T ATE205479T1 (de) | 1994-03-10 | 1995-03-08 | Naphtalen-derivate als prostaglandin i2 agonisten |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US5763489A (https=) |
| EP (1) | EP0749424B1 (https=) |
| JP (1) | JP3245864B2 (https=) |
| KR (1) | KR100383305B1 (https=) |
| CN (1) | CN1057522C (https=) |
| AT (1) | ATE205479T1 (https=) |
| AU (1) | AU688871B2 (https=) |
| CA (1) | CA2185104A1 (https=) |
| DE (1) | DE69522676T2 (https=) |
| DK (1) | DK0749424T3 (https=) |
| ES (1) | ES2160156T3 (https=) |
| GR (1) | GR3037080T3 (https=) |
| HU (1) | HU224822B1 (https=) |
| PT (1) | PT749424E (https=) |
| RU (1) | RU2155188C2 (https=) |
| TW (1) | TW282456B (https=) |
| WO (1) | WO1995024393A1 (https=) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2179399A1 (en) * | 1993-12-20 | 1995-06-29 | Kiyoshi Taniguchi | 4,5-diaryloxazole derivatives |
| TW401408B (en) | 1995-07-21 | 2000-08-11 | Fujisawa Pharmaceutical Co | Heterocyclic compounds having prostaglandin I2 agonism |
| DE19537548A1 (de) * | 1995-10-09 | 1997-04-10 | Merck Patent Gmbh | Endothelin-Rezeptor-Antagonisten |
| DE19604191A1 (de) * | 1996-02-06 | 1997-08-07 | Hoechst Schering Agrevo Gmbh | 2,4-Diamino-1,3,5-triazine, Verfahren zu deren Herstellung und deren Verwendung als Herbizide und Pflanzenwachstumsregulatoren |
| AUPO713297A0 (en) * | 1997-06-02 | 1997-06-26 | Fujisawa Pharmaceutical Co., Ltd. | Oxazole compound |
| GB9720270D0 (en) | 1997-09-25 | 1997-11-26 | Pharmagene Lab Limited | Medicaments for the treatment of migraine |
| AUPP003297A0 (en) | 1997-10-27 | 1997-11-20 | Fujisawa Pharmaceutical Co., Ltd. | 4,5-diaryloxazole compounds |
| AUPP029197A0 (en) * | 1997-11-10 | 1997-12-04 | Fujisawa Pharmaceutical Co., Ltd. | Benzocycloheptene derivatives |
| AUPP109097A0 (en) | 1997-12-22 | 1998-01-22 | Fujisawa Pharmaceutical Co., Ltd. | Napthalene derivatives |
| US6335459B1 (en) | 1998-12-23 | 2002-01-01 | Syntex (U.S.A.) Llc | Aryl carboxylic acid and aryl tetrazole derivatives as IP receptor modulators |
| US20040127529A1 (en) * | 1999-06-21 | 2004-07-01 | Fujisawa Pharmaceutical Co., Ltd. | Remedies for skin ulcer |
| AU5249200A (en) * | 1999-06-21 | 2001-01-09 | Fujisawa Pharmaceutical Co., Ltd. | Remedies for skin ulcer |
| WO2002042243A1 (fr) * | 2000-11-21 | 2002-05-30 | Fujisawa Pharmaceutical Co., Ltd | Processus de preparation de derives de tetrahydronaphtalene |
| JPWO2002085412A1 (ja) * | 2001-04-18 | 2004-08-05 | 藤沢薬品工業株式会社 | 組織線維化抑制剤 |
| ES2636943T3 (es) | 2003-05-09 | 2017-10-10 | Toray Industries, Inc. | Beraprost y un inhibidor del sistema renina-angiotensina para usar en el tratamiento de enfermedades renales |
| TWI417095B (zh) | 2006-03-15 | 2013-12-01 | Janssen Pharmaceuticals Inc | １，４-二取代之３-氰基-吡啶酮衍生物及其作為ｍＧｌｕＲ２-受體之正向異位性調節劑之用途 |
| ES2383239T3 (es) | 2006-12-14 | 2012-06-19 | Astellas Pharma Inc. | Compuestos de ácidos policíclicos útiles como antagonistas de CRTH2 y como agentes antialérgicos |
| TW200845978A (en) | 2007-03-07 | 2008-12-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives |
| TW200900065A (en) | 2007-03-07 | 2009-01-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives |
| PL2203439T3 (pl) | 2007-09-14 | 2011-06-30 | Addex Pharmaceuticals Sa | 1',3'-dipodstawione-4-fenylo-3,4,5,6-tetrahydro-2H, 1'H-[1, 4']bipirydynylo-2'-ketony |
| KR20230085944A (ko) | 2008-03-18 | 2023-06-14 | 아레나 파마슈티칼스, 인크. | 프로스타시클린 （ｐｇｉ２） 수용체와 관련된 장애의 치료에 유용한 상기 수용체의 조절제 |
| JP5547194B2 (ja) | 2008-09-02 | 2014-07-09 | ジャンセン ファーマシューティカルズ， インコーポレイテッド． | 代謝型グルタミン酸受容体の調節因子としての３−アザビシクロ［３．１．０］ヘキシル誘導体 |
| WO2010060589A1 (en) | 2008-11-28 | 2010-06-03 | Ortho-Mcneil-Janssen Pharmaceuticals, Inc. | Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors |
| MY153913A (en) | 2009-05-12 | 2015-04-15 | Janssen Pharmaceuticals Inc | 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
| MY153912A (en) | 2009-05-12 | 2015-04-15 | Janssen Pharmaceuticals Inc | 1, 2, 4,-triazolo[4,3-a[pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
| CN102439008B (zh) | 2009-05-12 | 2015-04-29 | 杨森制药有限公司 | 1,2,4-三唑并[4,3-a]吡啶衍生物及其用于治疗或预防神经和精神病症的用途 |
| CN103261195B (zh) | 2010-11-08 | 2015-09-02 | 杨森制药公司 | 1,2,4-三唑并[4,3-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途 |
| EP2661435B1 (en) | 2010-11-08 | 2015-08-19 | Janssen Pharmaceuticals, Inc. | 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS |
| PL2649069T3 (pl) | 2010-11-08 | 2016-01-29 | Janssen Pharmaceuticals Inc | Pochodne 1,2,4-triazolo[4,3-a]pirydyny i ich zastosowanie jako dodatnich allosterycznych modulatorów receptorów mGluR2 |
| JO3368B1 (ar) | 2013-06-04 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2 |
| JO3367B1 (ar) | 2013-09-06 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2 |
| KR20220049612A (ko) | 2014-01-21 | 2022-04-21 | 얀센 파마슈티카 엔.브이. | 대사 조절형 글루탐산 작동성 수용체 제2아형의 양성 알로스테릭 조절제 또는 오르토스테릭 작동제를 포함하는 조합 및 그 용도 |
| HUE053734T2 (hu) | 2014-01-21 | 2021-07-28 | Janssen Pharmaceutica Nv | 2-es altípusú metabotróp glutamáterg receptor pozitív allosztérikus modulátorait tartalmazó kombinációk és alkalmazásuk |
| EP3977985B1 (en) | 2017-03-01 | 2023-09-06 | Arena Pharmaceuticals, Inc. | Compositions comprising pgi2-receptor agonists and processes for the preparation thereof |
| US12098116B2 (en) | 2022-02-15 | 2024-09-24 | United Therapeutics Corporation | Crystalline prostacyclin (IP) receptor agonist and uses thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SU1366514A1 (ru) * | 1986-01-28 | 1988-01-15 | Днепропетровский химико-технологический институт им.Ф.Э.Дзержинского | Способ получени производных N-арил-5-ариламидо-4,6-диметилпиридона-2 |
| DE3837809A1 (de) * | 1988-11-08 | 1990-05-10 | Merck Patent Gmbh | Tetralinderivate |
| US5344836A (en) * | 1991-11-11 | 1994-09-06 | Ono Pharmaceutical Co., Ltd. | Fused benzeneoxyacetic acid derivatives |
-
1995
- 1995-03-08 WO PCT/JP1995/000373 patent/WO1995024393A1/en not_active Ceased
- 1995-03-08 RU RU96120174/04A patent/RU2155188C2/ru not_active IP Right Cessation
- 1995-03-08 TW TW084102192A patent/TW282456B/zh active
- 1995-03-08 CA CA002185104A patent/CA2185104A1/en not_active Abandoned
- 1995-03-08 JP JP52335695A patent/JP3245864B2/ja not_active Expired - Fee Related
- 1995-03-08 KR KR1019960704963A patent/KR100383305B1/ko not_active Expired - Fee Related
- 1995-03-08 AT AT95910763T patent/ATE205479T1/de not_active IP Right Cessation
- 1995-03-08 AU AU18618/95A patent/AU688871B2/en not_active Ceased
- 1995-03-08 PT PT95910763T patent/PT749424E/pt unknown
- 1995-03-08 CN CN95192846A patent/CN1057522C/zh not_active Expired - Fee Related
- 1995-03-08 DE DE69522676T patent/DE69522676T2/de not_active Expired - Fee Related
- 1995-03-08 US US08/702,546 patent/US5763489A/en not_active Expired - Fee Related
- 1995-03-08 DK DK95910763T patent/DK0749424T3/da active
- 1995-03-08 EP EP95910763A patent/EP0749424B1/en not_active Expired - Lifetime
- 1995-03-08 HU HU9602466A patent/HU224822B1/hu not_active IP Right Cessation
- 1995-03-08 ES ES95910763T patent/ES2160156T3/es not_active Expired - Lifetime
-
1998
- 1998-02-23 US US09/028,861 patent/US5863918A/en not_active Expired - Fee Related
-
2001
- 2001-10-31 GR GR20010401952T patent/GR3037080T3/el not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| AU1861895A (en) | 1995-09-25 |
| WO1995024393A1 (en) | 1995-09-14 |
| HU9602466D0 (en) | 1996-11-28 |
| TW282456B (https=) | 1996-08-01 |
| KR970701698A (ko) | 1997-04-12 |
| DE69522676T2 (de) | 2002-04-18 |
| GR3037080T3 (en) | 2002-01-31 |
| HK1013289A1 (en) | 1999-08-20 |
| HUT75226A (en) | 1997-04-28 |
| AU688871B2 (en) | 1998-03-19 |
| US5763489A (en) | 1998-06-09 |
| ES2160156T3 (es) | 2001-11-01 |
| EP0749424A1 (en) | 1996-12-27 |
| PT749424E (pt) | 2002-03-28 |
| HU224822B1 (en) | 2006-02-28 |
| KR100383305B1 (ko) | 2003-11-01 |
| JP3245864B2 (ja) | 2002-01-15 |
| US5863918A (en) | 1999-01-26 |
| CN1057522C (zh) | 2000-10-18 |
| EP0749424B1 (en) | 2001-09-12 |
| DE69522676D1 (de) | 2001-10-18 |
| JPH09509958A (ja) | 1997-10-07 |
| CA2185104A1 (en) | 1995-09-14 |
| RU2155188C2 (ru) | 2000-08-27 |
| DK0749424T3 (da) | 2001-11-26 |
| CN1147250A (zh) | 1997-04-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE205479T1 (de) | Naphtalen-derivate als prostaglandin i2 agonisten | |
| ATE306261T1 (de) | Antithrombosemittel | |
| ATE194335T1 (de) | 4,5-diaryloxazol-derivate | |
| IL133623A0 (en) | Antithrombotic agents | |
| TR199700844T1 (xx) | Pirazolil-Benzoil T�revleri. | |
| MX9800577A (es) | Derivados de 4,5-diaril oxazol. | |
| IL124537A0 (en) | Naphthyl-substituted benzimidazole derivatives and pharmaceutical compositions containing the same | |
| MEP24608A (en) | Azetidine derivatives, preparation thereof and pharmaceutical compositions containing same | |
| DE69325454D1 (de) | Taxol-derivate | |
| PT1074542E (pt) | Compostos de indole contendo sulfonamida | |
| TR200200579T2 (tr) | Amino-tirazolpiridin türevleri. | |
| BR0014651A (pt) | Inibidores de adesão de célula mediada por "alfa" l beta2 | |
| ATE232520T1 (de) | Imidazolidin-4-on derivate verwendbar als antikrebsmittel | |
| NO934536D0 (no) | Fenoksy- og fenoksyalkyl-pepiridiner som antivirale midler | |
| IT1255802B (it) | Derivati imidazolici ad attivita' a ii antagonista | |
| DE69107064D1 (de) | Indolderivate. | |
| HUP0103303A2 (hu) | Imidazolvegyületek, eljárás előállításukra, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények | |
| ATE157369T1 (de) | 3'-azaridino-anthracyclin-derivate | |
| HRP20010885B1 (en) | Ethanesulfonyl-piperidine derivatives | |
| DE69813886D1 (de) | Naphthalin derivate | |
| MX9603617A (es) | Derivados de naftaleno. | |
| ES2180640T3 (es) | Derivados glicosilados solubles en agua de compuestos 1,2-ditiinos. | |
| ES2132255T3 (es) | Nuevos compuestos de flavilio farmaceuticamente activos. | |
| TW329388B (en) | Intraocular irrigating solution | |
| DE69528984D1 (de) | Hemmung der leukotrienbiosynthese mittels harnstoffderivaten |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification | ||
| REN | Ceased due to non-payment of the annual fee |